Today news
About the same in other media
Cancer drug specialist Clinigen agrees to £1.2bn takeover
Reading now: 427
The cancer drug specialist Clinigen has agreed to a £1.2bn takeover deal from a London-based investment firm, becoming the latest big British company to be taken private.
Triton Investment Management has offered to pay 883p a share for the company, whose main product is the acquired cancer medicine Proleukin.
Clinigen, which is based in Burton-on-Trent, Staffordshire, said its board had recommended the offer to shareholders, which include the New York hedge fund Elliott Management, with a 7.6% stake.
The news sent Clinigen’s share price soaring by up to 15% in early trading, though they later settled at at 901p, up 10.2%.
Elliott declined to comment. It has been reportedly demanding a break-up of Clinigen, but never made its demands public –
Read more on theguardian.comAbout this in other media
BNP Paribas agrees to $16.3bn sale of Bank of the West to BMO Financial Group fnlondon.com /2 years ago
Peter Macnab: Superdrug boss leading the high street fightback theguardian.com /2 years ago
JPMorgan agrees to $125 million fine for letting employees use WhatsApp to evade regulators’ reach cnbc.com /2 years ago
Show more
The website finance-news.co. is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.
